# AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

> **NCT04881032** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Jean Perrin** · enrollment: 66 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
- **RADIATION:** radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04881032
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2025-09
- **Final completion:** 2027-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881032, "AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04881032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*